Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Canada (AMBER)

NCT02581189 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02581189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02581189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Canada (AMBER)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
October 13, 2015
Completion date
December 20, 2017
Enrollment
565 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c